Pharmaceutical Executive March 5, 2024
This marks the first time that a hyaluronic acid dermal filler has received FDA approval for temple hollowing.
Allergan Aesthetics, an AbbVie company, announced that the FDA has approved Juvéderm Voluma XC to treat moderate to severe temple hollowing in adults over 21 years of age. According to the company, the medication has the ability to yield results that last up to 13 months with peak treatment, with approximately 80% of test subjects reporting satisfaction with the outcomes. With this regulatory action, Juvéderm Voluma becomes the first hyaluronic acid (HA) dermal filler indicated for moderate to severe temple hollowing to be approved by the FDA.1
“The approval of Juvéderm Voluma XC to treat temple hollows further demonstrates Allergan Aesthetics commitment...
Today's Sponsors
Today's Sponsor